Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...